A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)

Open

Phase

Abbreviated Title

Status Notes

CTSU/A022101 has been endorsed and activated by SWOG, effective 22-Aug-2022. CTSU/A022101 was activated by ALLIANCE, effective 10-Jan-2023.

Activated

01/10/2023

Participants

ALLIANCE, ECOG-ACRIN, NRG, SWOG

Research committees

Gastrointestinal Cancer

Treatment

5-Fluorouracil Irinotecan Leucovorin Calcium Oxaliplatin Bevacizumab Capecitabine Cetuximab

Eligibility Criteria Expand/Collapse

Eligibility criteria are accessible from the protocol abstract page on the CTSU website (http://www.ctsu.org)

Publication Information Expand/Collapse

2023

A022101: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer - evaluating radiation, ablation, and surgery (ERASur)

K Hitchcock;P Romesser;Q Shi;J Dixon;S Gholami;S White;C Wu;C Goulet;K Jee;C Wright;R Yaeger;A Shergill;T Hong;T George;E O'Reilly;J Meyerhardt;E Miller J Clin Oncol 41, 2023 (suppl 16; abstr TPS3629); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster

Other Clinical Trials

SWOG Clinical Trial Number

S2303

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)

Research Committee(s)

Gastrointestinal Cancer

Activated

05/06/2024

Open

SWOG Clinical Trial Number

CTSU/A022101